KOREA
N01
Manufacturer
Drug Formulation (general category), Antisense, RNA, Biopharmaceuticals (general category)
Autotelic Bio is a biopharmaceutical company founded in 2015 and is developing mRNA-based anti-sense oligonucleotide (ASO) innovative new drugs and small-molecule new drugs.
We have a total of six pipelines under development, including two ASO anti-cancer drugs that selectively inhibit TGF-β, one ASO new drug drug that targets mutant KRAS G12V, one ALK5 targeting small molecular compound with IPF (Idiopathic Pulmonary Fibrosis) as target indication, and the world's first fixed dose combination to simultaneously treat hypertension and type 2 diabetes.
